Thursday, February 17, 2011

Hormone Refractory Prostate Cancer

Psa shooting up @ 100% every month - HealthBoards Message Boards

As you no doubt know, HRPC means Hormone Refractory Prostate Cancer; in layman's language, it means that the cancer is no longer controlable by hormonal therapy. There is a small community of like-thinking doctors specializing in treating prostate cancer in North America, especially advanced disease and challenging cases, that I am convinced has become much more expert and knowledgeable than most doctors treating the disease advanced disease. In particular, they have more or less reached a consensus in applying hormonal blockade. I am in my tenth year as a survivor, doing very well, following their advice on the particular approach known as intermittent triple hormonal blockade (with a bisphosphonate drug in support, a statin drug to help my odds of success, and a lifestyle program involving diet/nutrition/supplements (keyed around a Mediterranean diet), exercise and stress reduction). At diagnosis my PSA was 113.6, Gleason 4+3=7, all biopsy cores positive, most 100% cancer; however, a bone scan, a CT scan, and a ProstaScint scan were all essentially negative. I have twice achieved a PSA of less than (<) 0.01 using an ultrasensitive PSA test before switching to the "off therapy" phase. I'm giving this background so you will have an idea of my viewing point. I am a now savvy patient, but I have had no enrolled medical education.

Was there treatment in addition to the orchiectomy? That operation eliminates testosterone that is produced from the testes, but it does not control other sources of testosterone, its docking with cancer cells, or prevent its conversion to more dangerous DHT (dihydrotestosterone). The experts I follow would not consider a patient to be in the refractory HRPC state until he no longer responded to a combination of hormonal blockade, not just an orchiectomy or its medical equivalent. Your father may be able to find a doctor who understands this approach and could put it to work now, and see how your father responds.

These experts would insist on also using a drug in the "antiandrogen" class to block most of the docking with cancer cells as well as to create other beneficial effects. In the US, the preferred drug is Casodex; it is expensive, but it is more effective, more convenient, and better in its side effect profile. The most common alternative in the same antiandrogen class is flutamide. Other options that may be available are Nilandron (nilutamide) and Androcur (cyproterone acetate - not available in the US, I believe because of greater risk of cardiovascular complications).

They would also insist on adding a third class of drug, known as "5-alpha reductase inhibitors" (5-ARI). In the US, most of the experts favor Avodart, though finasteride, formerly known as Proscar, is also available (and is the drug I have been on). A few men do not respond well to Avodart because of a genetic problem, but they will respond to finasteride. (Incidentally, the first generic version of Proscar - finasteride - that I took was manufactured by the company run by the Indian doctor known as Dr. Reddy.) These 5-ARI drugs are highly effective in preventing conversion of any remaining testosterone to DHT, and they also cut down the supply of blood needed for tumor growth.

This program combined hormonal blockade program is compatible with chemotherapy.


He was treated from Jul 2008 to Jan 2009 for HRPC by weekly Chemotherapy , and simultaneously received injections every month for bone thickening .

Most likely he was getting infusions of a bisphosphonate drug. Aredia (Pamidronate) is the infusion drug that was commonly used until a much more powerful drug, Zometa, was approved by the US FDA (Food and Drug Administration) in 2001. Now that would be the strongly preferred drug for a case like your father's. It is quite expensive, but in the US it is usually well covered by insurance. It does have some potential side effects, especially when used frequently and long-term, but countermeasures can help to a degree. He should be taking calcium and vitamin D3 daily in support of the bisphosphonate therapy.

His PSA dropped to 7.72. He was on Hormanal therapy since then till Jun 09. His PSA started risign 100 % every month from Jan itselt, and has reached 132 now.

What a great response to chemotherapy! Since he had an orchiectomy, that is a permanent form of hormonal therapy. Were other drugs added since sometime last year? This is where using the full batch of drugs might make a critical difference. If not, the experts I follow switch to a more powerful antiandrogen, specifically ketoconazole with hydrocortisone in support. If that does not work, they will often try estrogen delivered through patches that are placed on the skin (known as "transdermal estrogen"). They may also use other agents, such as leukine.

In support of this, the doctor I follow most closely, Dr. Charles "Snuffy" Myers, MD, strongly advocates a lifestyle program.

Two excellent books describe hormonal therapy, other options I've mentioned, and the lifestyle program. They are: "A Primer on Prostate Cancer - The Empowered Patient's Guide," Dr. Stephen B. Strum, MD, and Donna Pogliano, and "Beating Prostate Cancer: Hormonal Therapy & Diet," by Dr. Myers.

There's a new drug that is highly likely to be approved by the FDA in the next six months in the US for men in your father's condition. It is known as Provenge. It is given by epheresis. It is also very expensive, but hopefully for US patients, insurance should help. I have not heard anything concrete about its international availability, but I do know that Dendreon, the company that developed the drug, is working on that.


At present he has an urge to pass urine every after 1/2 an hour, but he cannot empty the bladder full. Every time during urination, a little stool also comes out.

It someone can help me to know, if there is any way to stop the PSA rising, and if frequent urination problem can be treated?

The 5-ARI drugs were originally approved by the FDA for treating benign enlargement of the prostate. It's quite possible that they might help with the urination problem, and it's also possible that the enhanced hormonal blockade therapy might reduce the cancer in a way that would help with urination.

I hope that your father finds something that works.

Take care and good luck to you and your father,

Jim
Read more at http://www.healthboards.com/boards/showthread.php?t=702324&ktrack=kcplink

Wednesday, February 16, 2011

Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: A case report and short literature review

Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: A case report and short literature review
Volume 24Issue 4, Pages 313-317 (July 2006)


Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: A case report and short literature review

Masahiro Yashi, M.D.Corresponding Author Informationemail address, Fumihito Terauchi, M.D., Akinori Nukui, M.D.,Masanori Ochi, M.D., Masayuki Yuzawa, M.D., Yosuke Hara, M.D., Tatsuo Morita, M.D.
Received 3 June 2005; received in revised form 29 August 2005; accepted 30 August 2005.

Abstract

Background
Small-cell neuroendocrine carcinoma has been recognized as a rare histologic variant occurring in only 0.5% to 2% of prostatic primary tumors. However, recent autopsy studies suggest development to this phenotype in up to 10% to 20% of the cases with hormone-refractory disease.
Case Presentation
A case of conventional adenocarcinoma before androgen-ablation therapy but showing progression to small-cell neuroendocrine carcinoma at the recurrence. The immunohistochemistry of the tumor showed strong positive staining for progastrin-releasing peptide (ProGRP), a carboxy terminal region common to 3 precursors for gastrin-releasing peptide, but almost negative staining for chromogranin-A and prostate-specific antigen. Combination chemotherapy based on cisplatin and etoposide was effective for controlling the tumor progression for 7 months, and the serum ProGRP level correlated well to the clinical course. Neither objective nor subjective responses were observed to somatostatin analogue therapy performed in the late stage of disease.
Conclusions
The present case reminds the urologist that small-cell neuroendocrine carcinoma may be a variant form of disease recurrence during androgen ablation in advanced prostate cancer. A strategic approach for this phenotype evaluating serum neuroendocrine markers, such as ProGRP, should be taken when serum prostate-specific antigen does not reflect the disease state. This approach would allow one to choose alternative therapies targeting neuroendocrine cells other than androgen ablation.
Keywords: Prostate cancer , Small-cell carcinoma , Neuroendocrine marker ,Progastrin-releasing peptide


My channel TURP biopsy sample indicate this neuro endocrine feature & Onchosurgeon Dr.Kathiresan may decide alternative therapy after reviewing on 15th.March 2011 with PSA test.

Neuroendocrine Differentiation In Prostate Adenocarcinoma Biopsies And Its Correlation To Histological Grading

Neuroendocrine Differentiation In Prostate Adenocarcinoma Biopsies And Its Correlation To Histological Grading

Neuroendocrine Differentiation In Prostate Adenocarcinoma Biopsies And Its Correlation To Histological Grading

MĂDĂLINA MARCU(1), E. RADU(2), MARIA SAJIN(1)


Text Prostate adenocarcinoma is one of the most frequent malignant diseases in men. Patients are stratified according to disease extension: organ-confined cancer (pT1, T2) benefits of definitive therapy (radical prostatectomy, radiotherapy, neoadjuvant therapy), while extraprostatic tumor extension or metastasis are an indication for hormone therapy. Androgen deprivation of malignant cells is well established for the treatment of metastatc disease, recurrence after radical prostatectomy or radiotherapy and as neoadjuvant therapy. However, 18 to 36 month after an initial response to hormone therapy, most of the prostate carcinomas swich to a hormone resistant phenotype, entering into a more aggressive and ultimately fatal stage of disease [1].

Neuroendocrine (NE) cells are a distinct epithelial cell compartment of the normal human prostate gland. Their phenotype and range of endocrine secretion products are similar, but not identical to those of NE-like cells from prostate carcinoma. Neuroendocrine differentiation (NED) is seen in virtually all cases of prostatic carcinoma, mostly in a focal pattern; a number of studies pointed out that its extent is associated to hormone therapy refractory and aggressive disease. Yet neuroendocrine differentiation is included by the College of American Pathologists Consensus Statement 1999 in category III of prognostic and predictive factors (not sufficiently studied to demonstrate prognostic value) [2].

In prostate cancer extending beyond the organ limits, most of the studies pointed out a strog association between the extent of NE differentiation and aggressive disease, but there are conflicting conclusions regarding the value of NED as an independent prognostic factor. Increased NE differentiation was found to be associated with aggressive disease [3, 4], Gleason score [5, 6], anti-androgen thearpy failure [3] and survival [6, 7]. However, McWilliam concluded that detection of neuroendocrine differentiation in conventional prostatic adenocarcinoma is not an independent indicator of prognosis [6].

Only a few studies addressed the prognostic significance of NE differentiation in localized prostate cancer, and data collected on prostatic biopsies is even scarcer. Some results indicate that histological grade and NE differentiation seen in prostatectomy samples predicted progression in multivariate analysis [8] or disease specific survival [9]. NE differentiation was also considered an additional prognostic marker in radical prostatectomy samples [10] and a factor that significantly aggravate established adverse prognostic parameters such as nodal status, tumour stage, pretherapeutic PSA-level, and Gleason score [11]. However, other studies lead to diverging conclusions: the extent of neuroendocrine differentiation was not foud to be an independent prognostic factor for biochemical failure of therapy in multivariate analysis [12, 13].

Screening population at risk using serum PSA monitoring and clinical examination recently gained in frequency, leading to an increase in the proportion of low-grade adenocarcinoma that is diagnosed on prostate core biopsy. New prognostic factors would help identifying at this stage patients at risk for unfavorable evolution, that would benefit from alternate therapy. This study aims to find correlations between the extent of neurocrine differentiation and known factors of disease evolution such as histological grade, malignant cell proliferation and serum PSA levels.

Friday, February 11, 2011

My channel TURP surgery at Cancer Institute,Chennai

I have under gone almost all tests from 10th.Jan till month end and they decided to perform Channel TURP surgery to address my urinary problems first.This problem known as LUTS (Lower urinary tract symptoms) caused due to the enlargement of my Prostate gland (84.2gms). So this procedure has nothing to do with prostate cancer treatment but clearing the urine passage of the urethra.(see the picture in my previous posting)


I was admitted on 1st.Feb & after the surgical procedure on 2nd. evening, discharged on 5th.Feb. evening.
I have to visit the institute on 15th.Feb. for the review.